Ignite Creation Date:
2024-06-16 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06422663
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-13
First Post:
2024-03-19
Brief Title:
A Study To Evaluate The Treatment Pattern Of Moderate-to-Severe Asthma Patients In China
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Prospective Observational Multicentre Study To Evaluate The Treatment Pattern Of Moderate-to-Severe Asthma Patients In China
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PRESENT
Brief Summary:
This is a Prospective Observational Multicentre Study to describe treatment pattern changes of uncontrolled moderate-to-severe asthma patients in China Sponsor by Astrazeneca InvestmentChina Co LTD
Detailed Description:
This is a prospective observational multicentre study Approximately 500 moderate-to-severe asthma patients from 30 sites across China Patients will be treated following routine clinical practice Study measures will be collected at week 0 week 12 and week 24
The primary objective of PRESENT study is to describe treatment pattern changes of uncontrolled moderate-to-severe asthma patients in China
The primary objective of PRESENT study is to describe treatment pattern changes of uncontrolled moderate-to-severe asthma patients in China
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None